ERF Eurofins Scientific SE
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, QA-QC programme, and food and dietary supplement labelling services; biopharma, and clinical diagnostics. The company also offers consumer product testing, which include sustainability, testing, certifications and approvals, expert services and regulatory, inspections, audits, consumer research and sensory evaluation, and training courses; cosmetics and personal care; and electrical and electronics laboratories services. In addition, it provides environment testing, including maritime, water, air, soil, building material, pollution, waste, fuel/oil, microplastics, and radioactivity testing; and food and feed testing that include allergen, audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, GMO, heavy metal, melamine, microbiology, molecular biology, mycotoxin, nutritional analyses, organic contaminants, pesticide, veterinary drug, vitamin, and residual DNA testing. Further, the company provides forensic, genomic, maritime, materials and engineering, REACH, and sensory and consumer services, as well as in vitro diagnostics and PSS insourcing solutions. The company was founded in 1987 and is headquartered in Luxembourg, Luxembourg.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Eurofins Scientific (EPA: ERF)
›
Eurofins Scientific (EPA: ERF) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 65,000 employees.
The shares were at 85.62 EUR on 20 November 2026, up 50.0% over 52 weeks. Its 52-week range is 56.34 EUR to 89.28 EUR: the price is 4.1% below the high and 52.0% above the low.
At a market capitalisation of 14.65B EUR, it trades at 29.7 times trailing earnings and 18.1 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.8, a discount of 17% for ERF. It pays a dividend yielding 0.84% (it pays out 25% of its earnings), against a median of 0.73% among the dividend payers in that peer group.
Eurofins Scientific reports return on equity of 10.5%, an operating margin of 14.1% and revenue up 2.5% year over year.
Its debt exceeds its cash by 3.85B EUR, a debt-to-equity ratio of 0.98. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 14 analysts cover the stock, with an average rating of Hold; their mean price target of 74.78 EUR is 12.7% below the current price. The next earnings report is expected on 28 January 2027.